Benha Journal of Applied Sciences (BJAS) **print: ISSN 2356–9751**
Vol. (9) Issue (7) (2024), (97- 112) **online: ISSN 2356–976x**
http://bjas.bu.edu.eg

Mild Cognitive Impairment in Parkinson's disease Patients

Huda H. Abd El-Hafez[1], Victor S. Mikhael [1], Abd ELnaser A. Morad [1], Shorouk F. Abd Elmaksoud [1] and Mohamed R. Khodair[3]
[1] Neuropsychiatry Dept., Faculty of Medicine, Benha University, Benha, Egypt
[2] Neuropsychiatry Dept., Faculty of Medicine, October 6 University,Giza, Egypt
E-mail: Hudahossam1882018@gmail.com

Abstract
Background: The term "cognitive impairment" was first used in the 1980s to describe minor cognitive impairments in the setting of Alzheimer's disease were not severe enough to be classified as dementia. This idea has only just found application in the field of Parkinson's disease (PD), a condition characterized by cognitive impairments are prevalent even at the time of diagnosis. The use, interpretation, evaluation, predictive power of this idea, however, are all highly contentious. In this article, we take a look back at what is known about motor cognitive impairment (MCI) in PD from an epidemiological perspective, including contemporary classifications, underlying pathophysiology, detection techniques, ways to monitor cognitive involvement in PD, current debates in this field. Objective: The purpose of this review paper is to look at the characteristics of cognitive impairment in (PD), kinds of cognitive impairment in (PD) subgroups, pertinent risk factors in subgroups. Last but not least, the evolution of PD at both the individual community levels is greatly aided by as a clinical entity. Longitudinal studies using more sensitive visuospatial assessments should be conducted in the future to track the development of cognitive changes in PD. Definitions biomarkers will probably start to include multimodal assessments in addition to neuropsychological testing. Disease categorization, individualized therapy, early intervention are all possible outcomes of identifying the first stages of cognitive involvement. It will pave the way for more robust clinical studies prospective outcome metrics, which might lead to the development of medicines to halt the onset of dementia in Parkinson's disease.

Keywords: Cognitive Impairment; disease; disease.

1. Introduction

PD is a degenerative neurological disorder worsens time. Among its motor symptoms are bradykinesia, stiffness of the muscles, resting tremors, instability of the gait posture [1].

Cognitive, olfactory, sleep, anxiety, depression, autonomic dysfunction are nonmotor symptoms. Mental behavioral illnesses also fall under this category. cognitive impairment (PD-MCI) PD dementia (PDD) are forms of cognitive impairment in PD [2].

Every year, between 6 15% of patients will develop dementia. The likelihood of PDD progression in is 62% after 4 years, compared to just 20% in PD-NC [3].

Among newly diagnosed PD participants, 36% had cognitive impairment (MCI). The prodromal stage is not immune to cognitive impairment [4].

Subjects, their families, even physicians often disregard motor symptom impairment (MCI) because of the misconcealment of these symptoms.

Aging severe motor symptoms, particularly postural gait instability, are often accompanied dementia, which often develops in the latter stages of PD. There is now no effective therapy for PDD, the condition is often accompanied motor problems, hallucinations, mental illnesses, all of which diminish the quality of life of [5].

In order to postpone the onset of the illness enhance quality of life, it is essential to detect PDD early practice prophylactic measures. Aarslet al. [6] noted while MCI is most often associated memory, it has now been expanded to include additional areas of cognition including language, attention, visuospatial function, executive function.

Age, tardiness of illness start, male gender, depression, severe motor symptoms have been linked to in recent research [7].

Motor symptoms, particularly instability of posture gait, are more influential on cognitive impairment (MCI) [2]. Cognitive decline was less likely in those who were younger or had more education[8].

Examining the characteristics of cognitive impairment in PD, the different kinds of cognitive impairment in PD, the subgroups of important risk factors in PD were the goals of this study.-MCI.

2. disease

In 1817, Dr. James Parkinson first referred to Parkinson's disease (PD) as a "shaking palsy." This neurodegenerative illness is marked by both motor nonmotor symptoms, it progresses over time. The disease's deteriorating effects on movement muscular control have a major

clinical impact on patients, their families, caregivers[9].

But there is now no evidence environmental factors promote Parkinson's disease. About 10% of cases have a hereditary component; this is especially true for younger [10].

The Human Body

In Parkinson's disease, the basal ganglia, a group of nuclei situated at the base of the forebrain, are usually the main areas malfunction. The caudate putamen is a part of the striatum, the largest nuclear complex in the basal ganglia. According to research by [11], the striatum receives excitatory signals from several parts of the brain as well as inhibitory excitatory signals from the dopaminergic cells of the substantia nigra pars compacta (SNc).

View the figure below [12] to view an example of the subthalamic nucleus.



Fig. (1) The subthalamic nucleus (STN) (lavender) is shown in a sagittal slice taken 12 mm

laterally of the midline [13].

According to [13], the GPi's neuronal output is controlled by both direct indirect routes. This output supplies the thalamic nuclei, which in turn project to the main supplementary motor regions, tonic inhibitory input.

Broad categories of potential danger

The idea this illness has hereditary components is well acknowledged, although the exact amount of heritability is still up for discussion. So far, six comprehensive meta-analyses have connected 41 distinct genetic loci to PD etiology [14].

Environmental, genetic, ethnic variables may all contribute to the pathophysiology of PD, given the disease's varying incidence around the globe. More risk factors for PD may be uncovered future therapy preventative choices may be better informed by ongoing biomedical research in PD patients [15].

Causes effects

Motor structures of the basal ganglia are affected by PD, an extrapyramidal system condition. The disease is marked by reduced motor function loss of dopaminergic activity, which leads to the clinical symptoms of the disease [16].

In PD, dopaminergic function is lost due to the progressive degradation of neurons in the substantia nigra pars compacta (SNpc) project to the striatum (the nigrostriatal pathway) [17]. Furthermore, since dopamine normally inhibits cholinergic activity, its removal leads to both diminished thalamic activation increased cholinergic activity. New data suggests various levels of the neurological system are involved in PD's widespread global network failure [18].

Refractory proteolytic processes involving aberrant breakdown or overproduction affected by genetic alterations may be the secondary cause of their creation.

According to[19], αSyn proteins might be a future target for PD treatment since they form insoluble fibrils associated LBs, which can be caused by gene mutations affecting the alpha-synuclein (αSyn) protein.

Early (premotor) olfactory rapid eye movement (REM) symptoms of PD may be facilitated by lesion patterns in the dorsal nucleus, medulla, pons. In later stages of Parkinson's disease, lesions in the nigrostriatal

area contribute to the typical motor symptoms of the condition.

Just as LBs are in people dementia LBs (DLB), they are also linked to PD dementia. Motor aspects are more noticeable manifest sooner in PD than in DLB, which is one way in which the two conditions vary clinically [20].

Root cause

The exact cause of Parkinson's disease is unknown, however researchers believe environmental genetic factors work together to cause the majority of cases. According to [21], about 10% of Parkinson's disease cases may be attributed to recognized hereditary factors.

The very poisonous weed killer paraquat, as well as the fungicides maneb and mancozeb, are environmental variables almost quadruple the incidence of Parkinson's disease. [22] states although most of the investigated agents are no longer working in industrialized nations, some of them could be in less developed areas.

However, there is evidence MPTP-induced Parkinsonism shares a mechanism Parkinson disease, which is characterized by a decrease in mitochondrial complex I activity [23].

According to the oxidation hypothesis, glutathione normally expedites the clearance of hydrogen peroxide. However, insufficient clearance of hydrogen peroxide can result in the formation of extremely reactive hydroxyl radicals, which in turn can react the lipids found in cell membranes, leading to lipid peroxidation cell damage[24].

When it comes to genetic variables, concordance between genetically identical monozygotic (MZ) twins will be than between dizygotic (DZ) twins, who only share around half of their genes, if those factors play a significant role in a certain illness. According to [25], twin studies conducted in the early stages of Parkinson's disease often discovered poor concordance rates for MZ DZ couples.

Melanoma: A research done in 2017 indicated people Parkinson's disease had a nearly fourfold chance of having prior melanoma [26].

Type 2 diabetics were 32% more likely to get Parkinson's disease in old age compared to non-diabetic subjects in a large cohort study.

The outlook

Even though there is no proof levodopa slows the disease's progression, its clinical effects are likely to blame. According to research published by[9], the following clinical variables have the potential to be used as predictors of the pace of development of Parkinson disease:

In newly diagnosed Parkinson's disease, a age at beginning of first rigidity/hypokinesia is a predictor of a quicker rate of motor progression and an earlier development of cognitive decline dementia. Conversely, if levodopa is administered at the first sign of tremor, it is possible to anticipate a longer therapeutic effect and a less harmful course of the illness.

Patients postural instability/gait difficulties (PIGD), who are male have other comorbidities, may also grow more quickly in their motor skills.

Possible predictors of premature nursing home placement reduced survival include advanced age at start, dementia, decreased reactivity to dopaminergic treatment.

Clinical manifestations

Heat sensitivity is a typical symptom of thermoregulatory disorders, which may also manifest as excessive perspiration. Regardless of the stage of the illness, some may have neuropathic pain or nociceptive pain in their muscles joints. Part 5 of this essay will address the management of PD's nonmotor characteristics [27].

Furthermore, longer courses of treatment are associated an increased risk of treatment-related problems, such as dystonia dyskinesia, among diagnosed between the ages of 45 55 [28].

Final Result

Since PD cannot be definitively diagnosed through testing, a clinician must rely on the patient's medical history, physical examination, symptoms to arrive at a clinical diagnosis. This process also involves ruling out other possible diagnoses, such as essential tremor, multiple-system atrophy, DLB disease (Table 1)[29].

Table 1: Possible Distinguishing Factors Between Parkinson's Disease Other Conditions [26].

- Neurodegenerative dementia
- Tumor of the basal ganglia
- Minimal tremor in the key areas
- Blood clots in the brain
- Dysgenesis of the corticobasal plane
- Disease known as Creutzfeldt-Jakob
- Lewy body dementia
- Parkinsonism caused by drugs
- Metabolic factors (such as hypoparathyroidism, thyroid problems, or dietary deficits)
- Deterioration of several systems
- Hypotension in the brain
- Problems smell
- Loss of olivopontocerebellar tissue
- PTSD, PD, Parkinson's disease
- Stewardship of the supranuclear arteries

- Reticular dystrophy
- Hemorrhage underneath the dura mater

It is possible to overlook or postpone diagnosing Wilson's disease in younger patients (those less than 60 years old) due to a lack of stiffness bradykinesia. An intention-type tremor (tremor movement) increased head involvement is a typical manifestation of benign essential tremor. PD symptoms are not uncommon in DLB, however the condition is more often associated cognitive abnormalities visual hallucinations in patients[30].

Neuropsychiatric tests, sleep investigations, vision examinations may be added to the diagnostic toolbox for Parkinson's disease (PD) patients who report visual alterations, such aberrant color vision caused by changes in intraretinal dopaminergic transmission [26].

The doctor has determined the patient has Parkinson's disease. Traditional magnetic resonance imaging (MRI) and computed tomography (CT) scans show no abnormalities, and there are no diagnostic biomarkers for the condition at this time. Olfactory testing, positron emission tomography (SPECT), or positron emission tomography (PET) should not be routinely used to establish the existence of Parkinson disease [31].

It is necessary to assess the 24-hour urine copper excretion slit-lamp examine for Kayser-Fleischer rings if the ceruloplasmin is low. Patients multiple system atrophy (MSA) have been shown to have abnormal outcomes on urinary sphincter electromyography [32].

Atypical Parkinsonism (MSA), progressive supranuclear palsy (PSP), corticobasal ganglionic degeneration (CBD) are the most probable right diagnoses for movement disorder neurologists when a false diagnosis of Parkinson disease is made. Differentiating between Parkinson disease atypical Parkinsonism may be challenging early on in the illness's progression. Clinical are used to differentiate between these illnesses because there are no laboratory biomarkers for them either.

Testing for olfactory abnormalities may distinguish between PSP, CBD, Parkinson's disease; however, MSA also reduces olfactory function [29].

Diagnostic Imaging

Imaging magnetic resonance

Magnetic resonance imaging (MRI) may help rule out certain medical conditions, including as tumors, strokes, hydrocephalus, multiple infarct states, Wilson disease lesions. Patients without tremor, those acute or stepwise progression, those younger than 55 years old, or whose clinical presentation does not provide a high degree of diagnostic confidence should have an MRI. According to [33], this MRI shows the usual placement of a thalamic stimulator.

Fast spin-echo inversion recovery axial MRI of the posterior commissure (Figure 2) [9].

CT MRI scans

The decarboxylation of 18F-dopa into 18F-dopamine storage of the resulting compound in dopamine nerve terminals in the striatum determine the rate of striatal 18F accumulation. Dopamine neuron survival may be assessed using 18F-dopa PET scans.

In October 2019, the FDA authorized fluorodopa F18, also known as fluorodeoxyphenylalanine 18F-DOPA. This medication is used in conjunction positron emission tomography (PET) to assess persons who may be suffering from Parkinson's disease [34]. Tremor caused by idiopathic Parkinson disease (IPD) or Parkinson-plus syndromes (PPS) may be distinguished from essential tremor the use of this medication.

The use of ioflupane iodine-123 single-photon emission computed tomography (SPECT) scanning to detect early-stage Parkinson's disease was shown to be similar to clinical evaluation at 1-year follow-up, according to an analysis of data from two clinical studies [35].

Classification of Tumors

The main molecular abnormalities include an overactive caudate nucleus cholinergic neurons a degradation of dopamine-producing cells in the substantia nigra, leading to a decrease in striatal dopamine [36].

A spinal puncture

A levodopa study is essential for these people. Biopterin neopterin concentrations in cerebrospinal fluid (CSF) as well as the neurotransmitter metabolites homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), 3-methoxy-4-hydroxyphenylglycol (MHPG) are assessed in further testing for this disorder [37].

The degree of motor dysfunction was linked to T-tau α-synuclein, whereas Aβ1-42 P-tau181 were strong indicators of Parkinson's disease. According to [38], the PD phenotype characterized by postural instability gait disruption was linked to decreased concentrations of Aβ1-42 P-tau181, but the tremor-dominant intermediate phenotypes were unrelated.

Methods for Treatment

Thus, therapy is initiated based on the patient's doctor's assessment of when symptoms start to hinder functioning or cause social shame.

When starting therapy, there is no "best" medication; rather, the severity timing of the disease's development should be considered.

The disorder known as Parkinson's disease (PD) impacts many brain circuits.

Low acetylcholine levels in other routes cannot be treated L-DOPA, but, low dopamine levels may be alleviated. Furthermore, pharmacological responses vary across subtypes. Each patient's response symptoms are unique, therefore it's ultimately up to the doctor's judgment to choose the best course of action [39].

Medications target dopamine: Although the active ingredient dopamine itself cannot cross the blood-brain barrier, the analogue L-DOPA may. An enzyme called aromatic-L-amino-acid decarboxylase (AADC) another enzyme called catechol-O-methyltransferase (COMT) convert it to dopamine in the small intestine. The nigrostriatal terminals are then able to retain this transformed dopamine. Dopamine agonists, on the other hand, reduce the need for dopamine synthesis by acting directly on postsynaptic receptors[40].

Bruising, itching, discomfort, injection-site nodules (seen in as many as 70% of individuals) are among the potential adverse effects. Apomorphine has a risk of complications compared to deep-brain stimulation levodopa-carbidopa intestinal gel, which are two invasive treatments for severe PD [41].

inhibitors, such as rivastigmine, may alleviate cognitive impairment hallucinations/delusions brought on by late-stage Parkinson's disease. Other medications in this class include monoamine oxidase inhibitors, catechol O-methyltransferase inhibitors, N-methyl D-aspartate receptor antagonists.

Additional medications are given in addition to other treatments include amantadine memantine, which are putative NMDA receptor antagonists [1]. Second, PD disrupts glutamatergic transmissions, leading to an overactivation of NMDA receptors, which can worsen dyskinesias; third, they synergize dopaminergic agents, improving release turnover of dopamine in the striatal neurons; finally, they block acetylcholine NMDA receptors [42].

According to McCarthing et al. (2020), agonists may decrease levels of subthalamic nucleus aberrant glutamate transmission.

Early on, anticholinergic medications were the primary pharmacological agents used in the treatment of Parkinson's disease. They aim to restore the equilibrium between dopamine acetylcholine levels was altered by PD by acting as antagonists at choline receptors, which reduces the action of acetylcholine [43].

These medications are still accessible for the treatment of PD, albeit L-DOPA other centrally acting dopaminergic agonists have mostly supplanted them. Due to their low plasma drug concentrations, this therapeutic class of medicines has little pharmacokinetic data. It includes benztropine, biperiden, diphenhydramine, ethopropazine, orphenadrine, procyclidine, trihexyphenidyl [44].

While anticholinergic medicines may be used alone in the early stages of tremor-predominant PD, they are most often used in conjunction L-DOPA other prescription treatments [45].

The therapeutic potential of neurotrophic factors (NTFs) in the management of neurodegenerative disorders, such as PD, appears encouraging. The strong trophic effect glial cell line-derived neurotrophic factor (GDNF) exerts on cultured dopaminergic neurons makes it one of the most closely related NTFs linked to Parkinson's disease [46].

Improving medication transport across the blood-brain barrier is the most common use of nanomedicine. Since the process of L-DOPA dopamine agonist mediation across the blood brain barrier may also take place in peripheral tissues, this becomes even more crucial when dealing these drugs ([47].

One technique to get drugs past the brain's protective barrier is by intranasal administration, which uses the olfactory trigeminal pathways. According to[48], nanoparticles enhance this absorption mechanism.

Minimal Cognitive Decline

The most accurate way to describe cognitive impairment (MCI) is as a transitional or prodromal state; in this condition, people still have full capacity to do daily tasks, but they do worse on certain neuropsychological assessments, which raises the possibility they may develop dementia [49].

The main results showed the memory tests were where the MCI patients really fell short compared to the NC group, even if the scores on the other cognitive tests were about the same. Furthermore, there was no significant difference in the degrees of memory impairment between the AD MCI groups [50].

Causes effects

Dementia is not in moderate cognitive impairment (MCI), which is characterized by cognitive impairment is more severe than the typical age-related decline but retained functional abilities. It is known there are several subtypes of MCI. A typical way to categorize MCI is according to whether it is amnestic or nonamnestic [51].

Neurocognitive impairment (MCI) has several complicated causes. Pathologic changes in Alzheimer's disease are not yet associated dementia often generate amnestic cognitive impairment. Neuropathology compatible Alzheimer's disease has been detected in autopsies taken from amnestic cognitive impairment in certain research groups. According to [52], nonamnestic cognitive impairment (MCI) may be associated a variety of medical conditions, including cerebrovascular sickness, frontotemporal dementias (a precursor), or no disorder at all.

Root cause

There is a great deal of variation in the causes symptoms of cognitive impairment (MCI). Most amnestic MCI proceed to clinical AD within 6 years, which is not unexpected considering amnestic MCI generally stems from AD pathology [53].

A big population-based research from 2016 found no correlation between having general anesthesia developing cognitive impairment in people who were 40 above. Goodman-[54] found no association between MCI anesthetic exposure, either as a dichotomous variable or as a function of the total number of exposures.

Medical History

Background information: People who suffer from cognitive impairment (MCI) often express subjective nebulous signs of deteriorating cognitive function, which may be hard to differentiate from the normal aging process. Consistent the widely held belief amnestic MCI is the most frequent kind, memory loss is supposedly the most common symptom [55].

When dealing the same patient group, it might be challenging to distinguish between cognitive symptoms those caused by different degrees of sensory deprivation, such as hearing loss or loss of visual acuity. Motor deficiencies can further exacerbate this problem.

There isn't a single aspect of the physical exam is characteristic of MCI. In order to rule out possible causes of motor control impairment (MCI), such as thyroid disease, cobalamin deficiency, or venereal disease, it is important to perform a thorough physical examination as part of the overall evaluation. This will help identify any sensory or motor impairments could exacerbate or explain the symptoms. To determine the extent of cognitive impairment, it is essential to conduct a mental status examination, as pointed out by [56].

Signs of Cognitive Impairment

Research on impairment indicators is of the utmost importance if it may pave the way for the development of new pharmacological therapies for cognitive impairment. Decreased volume of the medial temporal lobe and the hippocampus, together with the presence of the Ab 40 Ab 42 proteins in plasma or cerebral spinal fluid, are two of the biomarkers may be used to identify individuals at a greater risk of developing dementia[57].

In contrast to an examination process obtains a thorough evaluation of neuropsychological daily functioning skills, neither biomarker has been shown to be a stronger predictor of prodromal AD [58].

Studying the Brain in Patients Cognitive Impairment

The categorization of MCI is based on a set of very general clinical for a diagnosis, rather than on psychometric to identify subgroups. For the last decade, large-scale clinical trial multisite efforts have adhered to the same protocol, for example, the Alzheimer's Disease Neuroimaging Initiative. One paragraph's delayed recall from the Wechsler Memory Scale - Logical Memory subtest is one of the four requirements of this scheme. The other two are a Clinical Dementia Rating score of 0.5 and normal general cognition, often indicated by a score of 24-30 on the Mini Mental State Exam (MMSE). Lastly, globally intact activities of daily living are the fourth criterion. Concerns about the sensitivity, stability, and clinical outcome prediction capabilities of such a global diagnostic strategy have been raised by [59].

Evaluation

Multiple cognitive impairment (MCI) sensitivity subtype specificity are both enhanced when two measurements from a single area of cognitive performance are used [60].

Tests for serial list learning provide a high-examination of the cognitive components underlying the existence of the episodic memory problem linked to cognitive impairment dementia. In a well-designed verbal serial list learning test, a battery of tests covering topics such as primacy recency effects, propensity for proactive retroactive interference, delayed free recall, delayed recognition, the generation of extra-list intrusion errors can be collected in a single administration. [61] cite recent qualitative work by Libon colleagues demonstrated how a nine-word serial list may be used for process error analysis.

Subtypes of cognitive impairment (MCI) may be more accurately diagnosed further research on the correlations between neuropsychological tests. For instance, according to[62], AD could be in cases of amnesic MCI have a flattened learning curve, poor recall recognition, a tendency for extra-

list intrusion errors. These symptoms characterize the classic profile of rapid forgetting.

Though the memory disorder may be more noticeable severe in cognitive impairment (MCI) caused by underlying cerebrovascular disease, the dysexecutive impairment in MCI linked to putative AD pathology may be less severe or widespread in comparison. It is feasible to have a combination of Alzheimer's disease cerebrovascular pathology when there are impairments in both executive function episodic memory, both deficits are equally impaired [63].

Intervention Supervision

The condition known as moderate cognitive impairment (MCI) has no known cure as of yet. While inhibitors have not been shown to postpone the development of dementia or Alzheimer's disease (AD) in people cognitive impairment (MCI), donepezil has been shown to postpone the progression to AD in depressed MCI patients without impacting their depressive symptoms[64].

The need to make a formal declaration on patients' capacity to manage their own affairs deserves special consideration. Unlike patients AD, who will inevitably need such assistance, those MCI often do not need to appoint power of attorney to anybody else as they are not demented by definition. Results from a study included 361 people Alzheimer's disease (AD), vascular dementia (CVD), or a combination of the two types of dementia showed CACE-Is may slow cognitive loss in dementia patients, independent of their blood pressure readings when diagnosed hypertension. Patients dementia who began using these medications had a rate of cognitive decline in the first six months [65].

Due to the high correlation between cognitive impairment (MCI) Alzheimer's disease (AD), as well as the fact MCI is a common precursor to AD, some experts have proposed intellectually taxing activities, such as brain teasers crossword puzzles, might be beneficial for people MCI. It is prudent to suggest these activities to people MCI, even if there is no conclusive evidence they are effective. It is important to ensure the patient is exercising at a manageable [66].

Patients cognitive impairment (MCI) should exercise often as a component of a broader strategy for symptom management, according to the 2017 revision of the American Academy of Neurology guideline on MCI, which has the support of the Alzheimer's Association. On the other hand, a 2018 BMJ research found little evidence vigorous exercise wards against dementia. [67]. (2019) reported out of 494 individuals, 329 were given an aerobic strength training program, whereas 165 were given normal care.

Cognitive Impairment in Parkinson's Disease: A Minor Aspect

A stage known as moderate cognitive impairment lies between the onset of dementia the natural aging process. According to[68], there are three subtypes of cognitive impairment (MCI) have been identified. These subtypes are a-MCI, which stands for amnestic MCI. Another subtype is md-MCI, which stands for multiple domain MCI. The letter 'a' indicates whether memory impairment is or not. Lastly, there is single nonmemory domain MCI.

Assessing a candidate at I (Abbreviated) or II (Comprehensive) depends on the amount of cognitive tests administered and the domains being evaluated. Contradictory results have been found in studies have examined characteristics. The long-held idea PD is characterized by a single nonmemory domain MCI is challenged by new findings suggesting two-thirds of patients have multiple domain subtype [69].

The term "cognitive impairment" (MCI) was first used in the 1980s to describe Alzheimer's disease-related cognitive impairments were not severe enough to be classified as dementia. Cognitive impairments are prevalent even at the time of diagnosis in Parkinson's disease (PD), which has led to the recent use of this notion in this context [70].

Why Is MCI Important?

Although the onset degree of dementia might vary greatly from person to person, half of all Parkinson's patients will have it within a decade after diagnosis.

Early intervention to delay or avert Parkinson's dementia is starting to seem like a viable possibility due to the availability of novel disease-modifying medicines for Parkinson’s. We can only expect for prognostic data if cognitive involvement is identified earlier. Thirdly, identifying people at risk of dementia, particularly those with early cognitive dysfunction, is crucial.

This can help those affected prepare for the future healthcare providers policymakers can anticipate the population's health social needs; (3) identifying the first signs of cognitive involvement could lead to new therapeutic targets by revealing the mechanisms cause diseases to progress [71].

Functional Impairment in People Who Do Not Have Parkinson's Disease

The term cognitive impairment (MCI) refers to a group of symptoms characterized by slower-than-average cognitive loss does not

significantly impact everyday functioning. It is separate from dementia, which is characterized by more severe cognitive impairments interfere daily living. According to Prichard, who identified forgetfulness of recent events as the first symptom of dementia in the nineteenth century, MCI was first proposed at time. According to [72], there are a number of words used to describe the gradual loss of cognitive abilities naturally occurs becoming older. These include memory impairment, benign senescent amnesia, cognitive decline.

An estimated 3-9% of the senior population suffers from cognitive impairment. Dementia conversion rates range from 11% to 33% during a 2-year period, the exact percentage varying by environment. It is worth mentioning after one year, 44% of MCI were found to be back to normal in a community context. On the other hand, estimates range from 16 to 18% every year for people screened in memory clinics who eventually develop dementia. rates reaching 41% after 1 year 64% after 2 years for amnestic MCI, memory-led MCI is an especially strong predictor of dementia [73].

MI in Parkinson's disease

Even in the earliest stages of PD, when symptoms of cognitive impairment may be lacking, the illness remains prevalent. Following in the footsteps of amnestic MCI in AD, the idea of is gaining traction as a transitional phase between normal cognition dementia [74].

Phenotypes of PD-MCI

affects several different areas of cognition varies greatly in phenotype, onset, course. In cases involving just one domain, this subtype is often not amnestic. Though it often encompasses impairments in several domains, subgroups primarily impact attention, memory, executive function, psychomotor speed, visuospatial skills have also been documented [75].

A Revision to the Definition of PD-MCI

The International Parkinson Movement Disorder Society (MDS) formed a task group to standardize the definition of after seeing it had differed among research. The definition was based on a literature analysis expert agreement.

To address the issue of inconsistent availability of neuropsychological testing across different clinical settings, the Task Force proposed a two-tiered definition. This pragmatic method permits the use of a shortened battery of neuropsychological tests or a global-scale cognitive assessment such as the Montreal Cognitive Assessment (MoCA) for the purpose of diagnosis [76].

At this of the criteria, impairment is defined as being on a global cognitive abilities scale or on two of the few neuropsychological tests are available [63].

For a more accurate evaluation, the second of uses a more extensive battery of tests covering all five areas of cognition: executive function, language, memory, attention working memory, visuospatial. For this evaluation, a battery of appropriate conventional neuropsychological tests might be used. According to [77], in order to identify deficiencies across all five cognitive domains, a minimum of two tests must be administered.

Progress from Cognitive Impairment to Parkinson's Disease Dementia

While PD-MCI is a strong predictor of PD dementia (PDD), longitudinal studies show the transition to PDD patterns is not always predictable and many patients regain normal cognition during follow-up. As contrast to individuals without cognitive involvement, 50% in a 5-year community-based Swedish trial, and 39% in the Norwegian ParkWest study, 62% of patients move to PDD during a 4-year follow-up [78].

Clinical Indications for MCI in Prodromal PD

Prior to the development of motor symptoms, during the prodromal phase of Parkinson's disease, cognitive impairments, particularly in fluency, might be identified. There is an increased chance of developing PD related poor cognitive performance, as indicated by the Stroop color test, verbal fluency, 15-word list learning tests.

Researchers have shown cognitive deficits can occur in who do not currently have Parkinson's disease but are at risk. This can be due to conditions such as REM sleep disorder or hyposmia. One study found unaffected relatives of people Parkinson's disease who had abnormal DaT scans hyposmia also demonstrated impaired performance on tests of processing speed, verbal fluency, attention [79].

Methods for Identifying Potential Victims

Some clinical risk factors for cognitive involvement in Parkinson's disease include: a rigid phenotype (freezing and/or falls, OR 1.8), an older age at diagnosis (age over 70, OR 5.2 in one study), low verbal fluency test scores, comorbidity rates, REM sleep behavioral disorder (OR 5.4), dysautonomia (OR 5.3 for systolic blood pressure drop, OR 5.3), and the presence of PD itself [80].

Biomarkers such as imaging CSF proteins are part of the for non-PD MCI but are not yet used for diagnosis. They may become significant as our understanding of how to

design therapies to slow the progression of dementia in PD grows [81].

CSF: Amyloid beta accumulation in the brain may be indicated by levels of CSF amyloid beta. There is a correlation between PDD PD patients' decreased CSF amyloid beta their results on verbal learning Stroop word color tests. Correlation between cerebrospinal fluid amyloid beta dementia risk in PD has also been found [82].

Radioligimaging: Radioligimaging has the ability to provide light on the cognitive processes involved in might serve as a clinically valuable indicator of MCI in PD.

Patients with PD show hypometabolism in posterior brain areas when compared to PD patients who do not have cognitive dysfunction, according to research by [63]. Furthermore, FDG-PET revealed decreased metabolism in posterior cortical areas in PD patients who acquired PD dementia after 6 years of follow-up.

Magnetic resonance imaging (MRI): Grey matter structural variations between non-involved reveal different patterns of atrophy affecting subcortical cortical brain areas. [75] speculate variations in cognitive testing MRI techniques used to measure cortical thickness contribute to these discrepancies.

White matter integrity information may be gleaned via diffusion-weighted imaging magnetic resonance imaging (MRI) methods, which are very sensitive to axonal injury. The total molecular displacement is shown by the estimated mean diffusivity (MD), whereas the pattern of diffusion restriction is indicated by the estimated fractional anisotropy (FA). Using FA MD, it was shown white matter alterations deteriorate worsening cognition in PD [83].

White matter abnormalities are seen in PD patients prior to changes in grey matter atrophy when the two measures are assessed simultaneously. Some new methods for measuring network-wide structural change are on the horizon, they should be sensitive to alterations [84].

The Essential Mechanisms of Cognitive Impairment-Positive Disorder

The etiology of cognitive involvement in Parkinson's disease is still largely unknown, and alpha synuclein is a key player in this. Unfortunately, PD-MCI data is sparse compared to dementia data in PD.

Reasons for this include the small number of cases detected after death the fact the illness manifests itself early in patients. The likelihood of being defined by many underlying diseases is growing [79].

In cognitive involvement in PD, the location of pathogenic accumulations inside afflicted cells, as well as the morphological properties of the proteins accumulated, seem to play a crucial role [85].

The synapse may play a crucial role in the early stages of Parkinson's disease (PD), which include cognitive functions. Unlike in normal conditions, when this protein is normally located at the presynaptic terminal, both PD DLB include aggregates of alpha synuclein attach to the synapses. Reduced levels of two synaptic proteins—neurogranin SNAP25 and neocortical ZnT3, a protein controls synaptic zinc—are associated with cognitive engagement in PD. One of the first hallmarks of Parkinson's disease is its involvement of the axonal compartment, where alpha synuclein builds up prior to the observation of neuronal death [86].

Potentially influential in PD-MCI are changes in the concentrations of certain neurotransmitters. Cognitive decline in Parkinson's disease is associated with cholinergic deficits in the brain's nucleus basalis of Meynert. Decreased choline acetyltransferase activity in the frontal and temporal lobes is associated with cognitive deficits caused by the Lewy body load. Cholinergic denervation is associated with worse verbal learning and Stroop performance in Parkinson's disease patients who do not have dementia [82].

Problems Disputes Now Existing

DLB plus PDD

Dementia Lewy bodies (DLB) Parkinson's disease (PD) dementia have been a topic of heated controversy for quite some time. Progressive cognitive impairment within the setting of established Parkinson's disease (PD) occurring at least one year following the beginning of Parkinsonian motor symptoms is known as Parkinson's disease dementia. In contrast, DLB refers to dementia develops before to, at the same time as, or during the first year of Parkinsonism. Cognitive impairments in preclinical prodromal Parkinson's disease raise serious concerns about the diagnostic for DLB [87].

There may be less distinction between PD DLB if cognitive alterations can be identified prior to classical PD's start; this would indicate a cognitive phenotype is fundamental to the PD diagnosis. The current for DLB from the Movement Disorder Society accept this problem, although it has not been rectified. [88] predict DLB, PDD, will have their meanings defined as our knowledge of the cognitive pathways involved in Parkinson's disease grows.

Other Health Issues Related to Parkinson's Disease

General levels of alertness attention, as well as cognition, may be affected by other PD-related variables. Medication side effects, changes in mood (such as sadness or indifference), problems sleeping are all examples of this. A person's intellect their global capacities in day-to-day functioning might be impacted by motor changes as well. All of these factors should be considered when evaluating patients for possible PD-MCI. Each of these aspects should be maximized via therapeutic treatments whenever feasible [89].

The Varieties of PD-MCI

According to the current definition, is a diverse group includes different degrees of impaired functioning deficiencies in any cognitive area. Preliminary data points to a risk of acquiring PD dementia in some subgroups, especially those impaired visuospatial function.

It is impossible to make reliable comparisons across research when cognitive profiles are not adequately distinguished broad are used. Most importantly, clinically valuable illness classification will be impossible so long as these lines remain unclear [84].

Treatments for Post-Disease MCI

Pharmacological: Though this is a growing field of study, there are no pharmaceutical therapies available at this time can enhance cognition in PD-MCI. The main outcome measure of global improvement showed a tendency for improvement in a recent modest cross-over trial of the rivastigmine patch. Recent studies on the selective noradrenaline reuptake inhibitor atomoxetine have shown promising results in improving global cognition in PD patients depression in PD patients without dementia, particularly in the areas of decision-making, attention, planning[90].

the hope of one day reducing the disease's progression, of disease-modifying treatments for Parkinson's are already active. Repurposing existing medications, immunotherapies directed against alpha synuclein, the lysosomal pathway are all potential targets. It is necessary to examine these therapies to see whether they can slow down cognitive involvement in PD or [91].

Non-Pharmacological: Despite several reports of cognitive training as a therapy for PD, the exact mechanism by which it improves cognition in this disease remains unknown. Notable methodological concerns were revealed in a recent meta-analysis of seven studies including 272 participants. Two of the seven trials lacked impartial evaluators, while another six were skewed due to a lack of adherence to intention-to-treat protocols. There isn't a lot of evidence, but it could have a minor influence on cognition overall, according to [92].

Executive abilities, including planning, showed the highest improvement, whereas scores on measures like the MMSE MoCA showed no increase at all. Significant improvements were not seen in the visuospatial memory areas. Cognitive outcomes in PD may be improved more effectively by exercise-based interventions.

According to many studies, both executive function language function may be improved moderate-intensity aerobic activities done two or three times weekly. It is crucial to evaluate the efficacy of these physical therapies in avoiding or reducing cognitive involvement in PD PD-MCI, large-scale RCTs are now under progress to do just [82].

3. Conclusions:

As a clinical entity, it considerably facilitates the progression of PD on both an individual and communal level. In order to monitor the progression of cognitive abnormalities in PD, future research should use longitudinal designs and more sensitive visuospatial measures. Neuropsychological testing isn't the only kind of evaluation that will likely start to be included into biomarker definitions. Identifying the first phases of cognitive involvement may lead to disease classification, personalized treatment, and early intervention. Better prospective outcome measures in clinical trials will be possible as a result, which could lead to the creation of medications to prevent dementia in Parkinson's disease.

References

[1] G.DeMaagd, & A. Philip. Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis. *P t,* vol.40, pp:504-32. 2015

[2] I., Litvan, D .,Aarsland C. H Adler., J. G Goldman., J., Kulisevsky, B., Mollenhauer, M. C Rodriguez-Oroz,., A. I Tröster,. & D Weintraub,.. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. *Mov Disord,* vol:26,pp: 1814-24.2011

[3] A.,B Sollinger F. C Goldstein,., J. J Lah,., A. I Levey,. & S. A Factor,.. Mild cognitive impairment in Parkinson's disease: subtypes and motor

characteristics. *Parkinsonism Relat Disord*, vol:16, pp:177-80. 2010

[4] Y Compta,. & M. J Martí,.. Parkinson disease: What goes around comes around: cognitive impairment as prodromal parkinsonism? *Nat Rev Neurol,vol:* 13,pp: 709-710. 2017

[5] P Prajjwal,., H. S Flores Sanga,., K Acharya,., T Tango,., J John,., R. S. C Rodriguez, M Dheyaa Marsool Marsool,., M Sulaimanov,., A Ahmed,. & O. A Hussin,.. Parkinson's disease updates: Addressing the pathophysiology, risk factors, genetics, diagnosis, along with the medical and surgical treatment. *Ann Med Surg (Lond)*, vol:85, pp:4887-4902. 2023

[6] D Aarsland,., K Andersen,., J Larsen,., A Lolk,. & P Kragh-Sørensen,.. Prevalence and Characteristics of Dementia in Parkinson Disease. *Archives of neurology*, 60, 387-92. 2003

[7] A Simon-Gozalbo,., C Rodriguez-Blazquez,., M. J Forjaz,. & P Martinez-Martin,.. Clinical Characterization of Parkinson's Disease Patients With Cognitive Impairment. *Front Neurol*, vol:11,pp: 731. 2020

[8] Q Wang,., Z .,Zhang L., Li, H Wen,. & Q ,Xu Assessment of cognitive impairment in patients with Parkinson's disease: prevalence and risk factors. *Clin Interv Aging*, vol:9, pp:275-812014.

[9] C .,Blauwendraat, M. A Nalls,. & A. B Singleton,.. The genetic architecture of Parkinson's disease. *Lancet Neurol,vol:* 19,pp: 170-178. 2020

[10] S Fanning,. D Selkoe,. & U Dettmer,. Parkinson's disease: proteinopathy or lipidopathy? *NPJ Parkinsons Dis,vol:* 6, pp:3. 2020

[11] K.,Seppi, K.,Ray Chaudhuri, M.,Coelho, S. H.,Fox, R.,Katzenschlager, S., Perez Lloret, D.Weintraub, & C.Sampaio,. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. *Mov Disord*, vol:34,pp: 180-198. 2019

[12] D.,Sulzer, A.,Antonini, V., Leta, A.,Nordvig, R. J.,Smeyne, J. E.,Goldman, O., Al-Dalahmah, L.,Zecca, A.,Sette, L.,Bubacco, O.,Meucci, E.,Moro, A. S.,Harms, Y.,Xu, S.Fahn, & K Ray Chaudhuri,.. COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. *NPJ Parkinsons Dis*, vol:6, pp:18. 2020

[13] G., Pagano, K. I.,Taylor, J.,Anzures-Cabrera, M.,Marchesi, T.,Simuni, K.,Marek, R. B.,Postuma, N.,Pavese, F.,Stocchi, J. P.,Azulay, B.,Mollenhauer, L.,López-Manzanares, D. S.,Russell, J. T., Boyd, A. P.,Nicholas, M. R.,Luquin, R. A.,Hauser, T.,Gasser, W.,Poewe, B.,Ricci, A.,Boulay, A.,Vogt, F. G.,Boess, J.,Dukart, G.,D'Urso, R.,Finch, S.,Zanigni, A.,Monnet, N.,Pross, A.,Hahn, H., Svoboda, M.,Britschgi, F.,Lipsmeier, E.,Volkova-Volkmar, M.,Lindemann, S.,Dziadek, Š.,Holiga, D.,Rukina, T.,Kustermann, G. A.,Kerchner, P.,Fontoura, D.,Umbricht, R., Doody, T.Nikolcheva, & A.Bonni,. Trial of Prasinezumab in Early-Stage Parkinson's Disease. *N Engl J Med*, vol:387,pp: 421-432. 2022

[14] A. E.,Lang, A. D.,Siderowf, E. A.,Macklin, W.,Poewe, D. J.,Brooks, H. H.,Fernandez, O.,Rascol, N.,Giladi, F.,Stocchi, C. M.,Tanner, R. B.,Postuma, D. K.,Simon, E.,Tolosa, B., Mollenhauer, J. M.,Cedarbaum, K.,Fraser, J.,Xiao, K. C., Evans, D. L.,Graham, I.,Sapir, J.,Inra, Hutchison, M.,R. M.,Yang, T.,Fox, S.Budd Haeberlein, & T.Dam,. Trial of Cinpanemab in Early Parkinson's Disease. *N Engl J Med*, vol:387, pp:408-420. 2022

[15] B. R.,Bloem, M. S.Okun, & C.Klein,. Parkinson's disease. *Lancet*, vol:397, pp:2284-2303.2021

[16] B. R.,Bloem, W Marks,. Jr.,J., Silva de A. L.,Lima, M. L.,Kuijf, T.,van Laar, B. P. F., M. M.,Jacobs, R. C.,Verbeek, Helmich, van de B. P.,Warrenburg, L. J. W., Evers, J.,intHout, van de T.,Zande, T. M.,Snyder R., Kapur, & M. J Meinders,.. The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease. *BMC Neurol*, vol:19, pp:160. 2019

[17] R. M. A.,de Bie, C. E.,Clarke, A. J.,Espay, S. H.Fox, & A. E.Lang,. Initiation of pharmacological therapy in Parkinson's

disease: when, why, and how. *Lancet Neurol*, vol:19, pp:452-461.2020.

[18] L.,Parnetti, L.,Gaetani, P.,Eusebi, S.,Paciotti, O.,Hansson, O.,El-Agnaf, B.,Mollenhauer, K.Blennow, & P.Calabresi,. CSF and blood biomarkers for Parkinson's disease. *Lancet Neurol*, 18, 573-586. 2019

[19] S. J.,Chia, E. K.Tan, & Y. X.Chao,. Historical Perspective: Models of Parkinson's Disease. *Int J Mol Sci*, vol:21pp: 2020

[20] A.,Mirelman, P.,Bonato, R.,Camicioli, T. D.,Ellis, N.,Giladi, J. L.,Hamilton, C. J.,Hass, J. M.,Hausdorff, E.Pelosin, & Q. J Almeida,.. Gait impairments in Parkinson's disease. *Lancet Neurol*, vol:18,pp: 697-708. 2019

[21] X.,Hou, J. O.,Watzlawik, F. C.Fiesel, & W.Springer,. Autophagy in Parkinson's Disease. *J Mol Biol*, vol:432,pp: 2651-2672. 2020

[22] M. E.,Johnson, B.,Stecher, V., Labrie, L.Brundin, & P.Brundin,. Triggers, Facilitators, and Aggravators: Redefining Parkinson's Disease Pathogenesis. *Trends Neurosci*, vol:42, pp:4-13. 2019

[23] M.,Elfil, S.,Kamel, M.,Kandil, B. B Koo,. & S. M.Schaefer,. Implications of the Gut Microbiome in Parkinson's Disease. *Mov Disord*, vol:35, pp:921-933.2020.

[24] J.,Horsager, K. B.,Andersen, K.,Knudsen, C.,Skjærbæk, T. D., Fedorova, N.,Okkels, E.,Schaeffer, S. K.,Bonkat, J.,Geday, M.,Otto, M.,Sommerauer, E. H.,Danielsen, E.,Bech, J.,Kraft, O. L.,Munk, S. D.,Hansen, N.,Pavese, R.,Göder, D. J.,Brooks, D. Berg, & P. Borghammer,. Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. *Brain*, vol:143, pp:3077-3088. 2020

[25] F.,Zhu, C.,Li, J.,Gong, W.,Zhu, L.Gu, & N.Li,. The risk of Parkinson's disease in inflammatory bowel disease: A systematic review and meta-analysis. *Dig Liver Dis,vol:* 51, pp:38-42. 2019

[26] K.,McFarthing, S.,Buff, G., Rafaloff, T., Dominey, R. K.Wyse, & S. R. W.Stott,. Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020. *J Parkinsons Dis*, vol:10,pp: 757-774. 2020

[27] Y. C.Tai, & C. H.Lin,. An overview of pain in Parkinson's disease. *Clin Park Relat Disord*, vol:2, pp:1-8. 2020

[28] L.,di Biase, P. M.,Pecoraro, S. P.,Carbone, M. L.Caminiti, & V.Di Lazzaro,. Levodopa-Induced Dyskinesias in Parkinson's Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions. *Journal of Clinical Medicine,vol:* 12,pp: 4427. 2023

[29] E.,Tolosa, A.,Garrido, S. W.Scholz, & W.Poewe,. Challenges in the diagnosis of Parkinson's disease. *Lancet Neurol*, vol:20,pp: 385-397. 2021

[30] M.Minen, & M Md,.. Emergence of Parkinsons Disease in Essential Tremor: A Study of the Clinical Correlates in 53 Patients. *Movement Disorders,vol:* 23, pp:1602-1605. 2008

[31] N. T.,Yao, Q., Zheng, Z. Q.,Xu, J. H.,Yin, L. G.,Lu, Q.,Zuo, S.,Yang, C. L.Zhang, & L.Jiao,. Positron emission computed tomography/single photon emission computed tomography in Parkinson disease. *Chin Med J (Engl)*, vol:133, pp:1448-1455. 2020

[32] R.,Xu, Y. F.,Jiang, Y. H. Zhang, & X.Yang, The optimal threshold of serum ceruloplasmin in the diagnosis of Wilson's disease: A large hospital-based study. *PLoS One*, vol:13,pp: e0190887. 2018.

[33] S. J.,Wang, H.,Geng, S. R., Cheng, C. C.,Xu, R. Q.,Zhang, Y., Wu, T., Wang, B.,Li, T.,Wang, Y. S.,Han, Z. H.Ding, , Y. N.,Sun, X.,Wang, Y. Z.Han, & N.Cheng,. A weighted cranial diffusion-weighted imaging scale for Wilson's disease. *Front Neurosci*, vol:17,pp: 1186053. 2023

[34] H.,Jiang, M. K.Jain, & H.Cai,. HPLC-free and cassette-based nucleophilic production of [(18)F]FDOPA for clinical use. *Am J Nucl Med Mol Imaging*,vol:11,pp: 290-299. 2021

[35] J.,Villena-Salinas, S. J.,Ortega-Lozano, T.,Amrani-Raissouni, E.Agüera, & Caballero- J.Villarraso,. Diagnostic Effectiveness of [(123)I]Ioflupane Single Photon Emission Computed Tomography (SPECT) in Multiple System Atrophy. *J Clin Med*, vol:12pp:. 2023

[36] S.Ramesh, & A.Arachchige,. Depletion of dopamine in Parkinson's disease and relevant therapeutic options: A review of the literature. *AIMS Neurosci,vol:* 10, pp:200-231. 2023

[37] A. B.,Burlina, A.,Celato, G.,Polo, C Edini,. & A. P Burlina,.. The Utility of CSF for the Diagnosis of Primary and Secondary Monoamine Neurotransmitter Deficiencies. *Ejifcc,* 28, 64-76.2017

[38] L.-J.,Zuo, Y.-S.,Piao, L.-X.,Li, S.-Y.Yu, , P.,Guo, Y.,Hu, T.-H.Lian, , R.-D.,Wang, Q.-J.,Yu, Z.,Jin, Y.-J.,Wang, X.-M.,Wang, P.,Chan, S.-D.,Chen, Y.-J.Wang, & W.Zhang,. Phenotype of postural instability/gait difficulty in Parkinson disease: relevance to cognitive impairment and mechanism relating pathological proteins and neurotransmitters. *Scientific Reports,vol:* 7, pp:44872.

[39] K. L. Tori, & L. Y.Eva,. A review on Parkinson's disease treatment. *Neuroimmunology and Neuroinflammation,* vol:8,pp: 222. 2021

[40] M.,Beckers, B. R Bloem,. & M. M Verbeek,.. Mechanisms of peripheral levodopa resistance in Parkinson's disease. *npj Parkinson's Disease,vol:* 8,pp: 56.2022.

[41] F.,Carbone, A.,Djamshidian, K.Seppi, & W.Poewe,. Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations. *CNS Drugs,* vol:33, pp:905-918. 2019

[42] T.Kikuchi,. Is Memantine Effective as an NMDA Receptor Antagonist in Adjunctive Therapy for Schizophrenia? *Biomolecules,* vol:10, pp:1134. 2020

[43] R.,Mahmoudi, J. L.,Novella, S.,Laurent-Badr, S., Boulahrouz, D.,Tran, I.Morrone, & Y.Jaïdi,. Cholinergic Antagonists and Behavioral Disturbances in Neurodegenerative Diseases. *International Journal of Molecular Sciences,* vol:24, pp:6921. 2023

[44] K.Kawabata, & M.Katsuno,. Trihexyphenidyl, Biperiden, and Other Anticholinergics in the Treatment of Parkinson's Disease. 2022

[45] W.,Pirker, R.,Katzenschlager, M.Hallett, & W.Poewe,. Pharmacological Treatment of Tremor in Parkinson's Disease Revisited. *J Parkinsons Dis,* vol:13,pp: 127-144. 2023

[46] Y.,El Ouaamari, J., Van den Bos, B.,Willekens, N.Cools, & I.Wens,. Neurotrophic Factors as Regenerative Therapy for Neurodegenerative Diseases: Current Status, Challenges and Future Perspectives. *Int J Mol Sci,* vol:24pp:. 2023

[47] G.,Cheng, Y.,Liu, R.,Ma, G.,Cheng, Y.,Guan, X.,Chen, Z.Wu, & T.Chen,. Anti-Parkinsonian Therapy: Strategies for Crossing the Blood-Brain Barrier and Nano-Biological Effects of Nanomaterials. *Nanomicro Lett,* vol:14,pp: 105. 2022

[48] Q.,Huang, X.,Chen, S.,Yu, G.Gong, & H.Shu,. Research progress in brain-targeted nasal drug delivery. *Front Aging Neurosci,* vol:15, pp:1341295.2023.

[49] C.,Baiano, P., Barone, L.Trojano, & G Santangelo,.. Prevalence and clinical aspects of mild cognitive impairment in Parkinson's disease: A meta-analysis. *Mov Disordvol:,* 35,pp: 45-54. 2020

[50] H.,Shen, X.,Zhu, Z.,Zhang, S.-H.,Wang, Y.Chen, , X.Xu, & J.Shao,. Heterogeneous data fusion for predicting mild cognitive impairment conversion. *Information Fusion,* vol:66, pp:54-63. 2021

[51] M. D. C.,Díaz-Mardomingo, S.,García-Herranz, R.,Rodríguez-Fernández, C.Venero, & H.Peraita,. Problems in Classifying Mild Cognitive Impairment (MCI): One or Multiple Syndromes? *Brain Sci,* vol:7 pp:. 2017

[52] N. C.,Cullen, A.,Leuzy, S.,Palmqvist, S., Janelidze, E.,Stomrud, P.,Pesini, L.,Sarasa, J. A.,Allué, N. K.,Proctor H.,, Zetterberg, J. L.,Dage, K.,Blennow, N.Mattsson-Carlgren, & O.Hansson,. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. *Nat Aging,* vol:1, pp:114-123. 2021

[53] A.,Tsapanou, J. D.,Papatriantafyllou, K.,Yiannopoulou, D.,Sali, F., Kalligerou, E.,Ntanasi, P.,Zoi, E.,Margioti, V.,Kamtsadeli, M.,Hatzopoulou, M.,Koustimpi, A.,Zagka, S. G.Papageorgiou, & P.Sakka,. The impact

of COVID-19 pandemic on people with mild cognitive impairment/dementia and on their caregivers. *Int J Geriatr Psychiatry*, vol:36,pp: 583-587. 2021

[54] J. M., Goodman-Casanova, E.,Dura-Perez, J.,Guzman-Parra, A.Cuesta-Vargas, & F.Mayoral-Cleries,. Telehealth Home Support During COVID-19 Confinement for Community-Dwelling Older Adults With Mild Cognitive Impairment or Mild Dementia: Survey Study. *J Med Internet Res,vol:* 22, pp:e19434. 2020

[55] C.,Gillis, F.,Mirzaei, M.,Potashman, M. A.Ikram, & N.Maserejian,. The incidence of mild cognitive impairment: A systematic review and data synthesis. *Alzheimers Dement (Amst)*, vol:11,pp: 248-256. 2019

[56] I.,Arevalo-Rodriguez, N.,Smailagic, M.,Roqué-Figuls, A.,Ciapponi, E., Sanchez-Perez, A.,Giannakou, O. L.,Pedraza, X Bonfill Cosp,. & S.Cullum,. Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev,vol: 7, pp:Cd010783. 2021

[57] J.Cummings,. The Role of Biomarkers in Alzheimer's Disease Drug Development. Adv Exp Med Biol, vol:1118,pp: 29-61. 2019

[58] E.,Irazoki, L. M.,Contreras-Somoza, J. M.,Toribio-Guzmán, C.,Jenaro-Río, H.van der Roest, & M. A.Franco-Martín,. Technologies for Cognitive Training and Cognitive Rehabilitation for People With Mild Cognitive Impairment and Dementia. A Systematic Review. Front Psychol, vol:11,pp: 648. 2020

[59] G. D., Rabinovici, C.,Gatsonis, C.,Apgar, K., Chaudhary, I.,Gareen, L., Hanna, J., Hendrix, Hillner, B. E., Olson, C., Lesman-Segev, O. H., Romanoff, J., Siegel, B. A., Whitmer, R. A. & M. C.Carrillo,. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. Jama, vol:321,pp: 1286-1294. 2019

[60] A.,Piau, K.,Wild, N.Mattek, & J.Kaye,. Current State of Digital Biomarker Technologies for Real-Life, Home-Based Monitoring of Cognitive Function for Mild Cognitive Impairment to Mild Alzheimer Disease and Implications for Clinical Care: Systematic Review. J Med Internet Res,vol: 21, pp:e12785. 2019

[61] N.,Thapa, H. J.,Park, J. G.,Yang, H.,Son, M.,Jang, J.,Lee, S. W.,Kang, K. W.Park, & H.Park,. The Effect of a Virtual Reality-Based Intervention Program on Cognition in Older Adults with Mild Cognitive Impairment: A Randomized Control Trial. J Clin Medvol:, 9pp:. 2020

[62] Y. Y.,Liao, H. Y.,Tseng, Y. J.,Lin, C. J.Wang, & W. C.Hsu,. Using virtual reality-based training to improve cognitive function, instrumental activities of daily living and neural efficiency in older adults with mild cognitive impairment. Eur J Phys Rehabil Med, vol:56,pp: 47-57. 2020

[63] R.,Baschi, A.,Luca, A., Nicoletti, M.,Caccamo, C. E., Cicero, C., D'Agate, L.,Di Giorgi, G., La Bianca, T.,Lo Castro, M.Zappia, & R.Monastero,. Changes in Motor, Cognitive, and Behavioral Symptoms in Parkinson's Disease and Mild Cognitive Impairment During the COVID-19 Lockdown. Front Psychiatry, vol:11,pp: 590134. 2020

[64] S.,Craft, R.,Raman, T. W.,Chow, M. S.,Rafii, C. K.Sun, R. A.,Rissman, M. C.,Donohue, J. B., Brewer, C.,Jenkins, K.,Harless, D.Gessert, & P. S.Aisen,. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA Neurol, vol:77, pp:1099-1109. 2020

[65] S.,Kasper, C.,Bancher, A.,Eckert, H.,Förstl, L.,Frölich, J.,Hort, A. D.,Korczyn, R. W.,Kressig, O.Levin, & M. S. M.Palomo,. Management of mild cognitive impairment (MCI): The need for national and international guidelines. World J Biol Psychiatry, vol:21, pp:579-594. 2020

[66] M.,Fortier, C. A.,Castellano, V.,St-Pierre, É.,Myette-Côté, F.,Langlois, M.,Roy, M. C.,Morin, C.,Bocti, T.,Fulop, J. P.,Godin,

C.,Delannoy, B.Cuenoud, & S. C.Cunnane,. A ketogenic drink improves cognition in mild cognitive impairment: Results of a 6-month RCT. Alzheimers Dement, vol:17, pp:543-552. 2021

[67] S.,Basaia, F.,Agosta, L.,Wagner, E.,Canu, G.,Magnani, R Santangelo,. & M Filippi,.. Automated classification of Alzheimer's disease and mild cognitive impairment using a single MRI and deep neural networks. Neuroimage Clin,vol: 21, pp:101645. 2019

[68] D., Zheng, C.,Chen, W.,Song, Z.,Yi, P.,Zhao, J.,Zhong, Z.,Dai, H.Shi, & P.Pan,. Regional gray matter reductions associated with mild cognitive impairment in Parkinson's disease: A meta-analysis of voxel-based morphometry studies. Behav Brain Res,vol: 371, pp:111973. 2019

[69] M.,Schmitter-Edgecombe, C.McAlister, & D.Greeley,. A Comparison of Functional Abilities in Individuals with Mild Cognitive Impairment and Parkinson's Disease with Mild Cognitive Impairment Using Multiple Assessment Methods. J Int Neuropsychol Socvol:, 28,pp: 798-809. 2022

[70] L. F. R.,Vasconcellos, J. S.,Pereira, H.,Charchat-Fichman, D.,Greca, M.,Cruz, A. L.Blum, & M.Spitz,. Mild cognitive impairment in Parkinson's disease: Characterization and impact on quality of life according to subtype. Geriatr Gerontol Int, vol:19,pp: 497-502. 2019

[71] D.,Hünerli, D. D.,Emek-Savaş, B.,Çavuşoğlu, B.,Dönmez Çolakoğlu, E.Ada, & G. G.Yener,. Mild cognitive impairment in Parkinson's disease is associated with decreased P300 amplitude and reduced putamen volume. Clin Neurophysiol, vol:130,pp: 1208-1217. 2019

[72] M.,Chaturvedi, J. G.,Bogaarts, V. V.Kozak Cozac, , F.,Hatz, U.,Gschwandtner, A.,Meyer, P.Fuhr, & V.Roth,. Phase lag index and spectral power as QEEG features for identification of patients with mild cognitive impairment in Parkinson's disease. Clin Neurophysiol, vol:130, pp:1937-1944. 2019

[73] M., Filippi, E.,Canu, G.,Donzuso, T.,Stojkovic, S.,Basaia, I., Stankovic, A., Tomic, V.,Markovic, I.,Petrovic, E.,Stefanova, V. S.Kostic, & F.Agosta,. Tracking Cortical Changes Throughout Cognitive Decline in Parkinson's Disease. Mov Disord, vol:35, pp:1987-1998. 2020

[74] X., Li, Y.,Jia, K.,Li, P.Liang, & X.Fu,. Precuneus Dysfunction in Parkinson's Disease With Mild Cognitive Impairment. Front Aging Neurosci, vol:10, pp:427. 2018

[75] V.,Orgeta, K. R.,McDonald, E.,Poliakoff, J. V.,Hindle, L.Clare, & I.Leroi,. Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev, vol:2,pp: Cd011961. 2020

[76] C.,Daniels, J.,Rodríguez-Antigüedad, E.,Jentschke, J.Kulisevsky, & J.Volkmann,. Cognitive disorders in advanced Parkinson's disease: challenges in the diagnosis of delirium. Neurol Res Pract, vol:6, 14. 2024

[77] Y.,Uchida, H.,Kan, K.,Sakurai, N.,Arai, D.,Kato, S.,Kawashima, Y.Ueki, & N.Matsukawa,. Voxel-based quantitative susceptibility mapping in Parkinson's disease with mild cognitive impairment. Mov Disord, vol:34,pp: 1164-1173. 2019

[78] C., Lv, L.,Fang, S.,Mao, H.Dong, & B.Liu,. Cognition Deficits in Parkinson's Disease: Mechanisms and Treatment. Parkinsons Dis, vol:2020,pp: 2076942. 2020

[79] T. R.,Melzer, M. R.,Stark, R. J.,Keenan, D. J.,Myall, M. R.,MacAskill, T. L.,Pitcher, L.,Livingston, S.,Grenfell, K. L.,Horne, B. N.,Young, M. J., Pascoe, M. M.,Almuqbel, J., Wang, S. H.,Marsh, D. H.,Miller, J. C.Dalrymple-Alford, & T. J.Anderson,. Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease. Front Neurol, vol:10, pp:391. 2019

[80] M. P.,Cecchini, A.,Federico, A.,Zanini, E.,Mantovani, C.,Masala, M.Tinazzi, & S. Tamburin,. Olfaction and taste in Parkinson's disease: the association with mild cognitive impairment and the single cognitive domain dysfunction. J Neural Transm (Vienna), vol:126, pp:585-595. 2019

[81] T.,Ren, Y.,Gao, Y.,Qiu, S.,Jiang, Q.,Zhang, J.,Zhang, L.,Wang, Y.,Zhang, L.Wang, & K.Nie,. Gut Microbiota Altered in Mild Cognitive Impairment Compared With Normal Cognition in Sporadic Parkinson's Disease. Front Neurol, vol:11,pp: 137. 2020

[82] E. R.,Wallace, S. C.,Segerstrom, C. G.,van Horne, F. A.Schmitt, & L. M.Koehl,. Meta-Analysis of Cognition in Parkinson's Disease Mild Cognitive Impairment and Dementia Progression. Neuropsychol Rev,vol: 32,pp: 149-160. 2022

[83] B. A.,Mueller, K. O.,Lim, L.Hemmy, & J.Camchong,. Diffusion MRI and its Role in Neuropsychology. Neuropsychol Rev, vol:25, pp:250-71. 2015

[84] A.,Nicoletti, A.,Luca, R.,Baschi, C. E.,Cicero, G.,Mostile, M.,Davì, L.,Pilati, V.,Restivo, M.Zappia, & R.Monastero,. Incidence of Mild Cognitive Impairment and Dementia in Parkinson's Disease: The Parkinson's Disease Cognitive Impairment Study. Front Aging Neurosci, vol:11, pp:21. 2019

[85] T. L.,Spires-Jones, J. Attems, & D. R.Thal,. Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol, vol:134,pp: 187-205.2017.

[86] Burré, J. The Synaptic Function of α-Synuclein. J Parkinsons Dis,vol : 5,pp: 699-713. 2017.2015.

[87] Borghammer, P., Okkels, N. & Weintraub, D. Parkinson's Disease and Dementia with Lewy Bodies: One and the Same. J Parkinsons Dis, vol:14,pp: 383-397. 2024

[88] P.,Gonzalez-Latapi, E.,Bayram, I.Litvan, & C.Marras,. Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors. Behav Sci (Basel), vol:11. pp:2021

[89] J.Mack, & L.Marsh,. Parkinson's Disease: Cognitive Impairment. Focus (Am Psychiatr Publ), vol:15, pp:42-54. 2017

[90] J. Y Szeto,. & S. J.Lewis,. Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia. Curr Neuropharmacol, vol:14, pp:326-38. 2016

[91] S.,Menon, S.,Armstrong, A.,Hamzeh, N. P.,Visanji, S. P.Sardi, & A.Tandon,. Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies. Front Neurol, vol:13, pp:852003. 2022

[92] B.,Guglietti, D.Hobbs, & L. E.Collins-Praino,. Optimizing Cognitive Training for the Treatment of Cognitive Dysfunction in Parkinson's Disease: Current Limitations and Future Directions. Front Aging Neurosci, vol:13, pp:709484. 2021